The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Safety and efficacy of sequencing high-dose interleukin 2 (IL2) after tyrosine kinase inhibitor (TKI) therapy for metastatic renal cell carcinoma.
E. T. Lam
No relevant relationships to disclose
M. K. K. Wong
Consultant or Advisory Role - Prometheus
Honoraria - Speaker's Bureau
N. Agarwal
No relevant relationships to disclose
B. G. Redman
Stock Ownership - Novartis (I)
T. Logan
Consultant or Advisory Role - Argos Therapeutics; Bristol-Myers Squibb; Genentech; GlaxoSmithKline; Novartis; Pfizer; Prometheus; Wyeth
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Pfizer; Prometheus; Wyeth
T. W. Flaig
Research Funding - Bayer; GlaxoSmithKline; Novartis; Onyx; Pfizer
J. P. Monk
Consultant or Advisory Role - Bayer; Genentech; Onyx
Research Funding - Prometheus
A. Jarkowski
No relevant relationships to disclose
A. Sendilnathan
No relevant relationships to disclose
M. Bolden
No relevant relationships to disclose
T. Kuzel
Consultant or Advisory Role - Boehringer Ingelheim; Centocor Ortho Biotech; Genentech; Prometheus; Roche
Honoraria - Genentech; Novartis; Pfizer; Prometheus
Research Funding - Bayer; Novartis; Onyx
T. Olencki
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Research Funding - Genentech; GlaxoSmithKline; Pfizer